Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 May;170(5):1158-65.
doi: 10.1111/bjd.12862.

Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network

J M P A van den Reek  1 , P P M van Lüumig, M E Otero, J Zweegers, P C M van de Kerkhof, P M Ossenkoppele, M D Njoo, J M Mommers, M I A Koetsier, W P Arnold, B A M Sybrandy-Fleuren, A L A Kuijpers, M P M Andriessen, M M B Seyger, W Kievit, E M G J de Jong
Affiliations
Comparative Study

Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network

J M P A van den Reek et al. Br J Dermatol. 2014 May.

Erratum in

  • Br J Dermatol. 2014 Jun;170(6):1382

Abstract

Background: Although the effectiveness of biologics for psoriasis has been measured extensively with objective outcome measures, studies based on subjective, patient-reported outcome measures remain scarce.

Objectives: To investigate satisfaction with medication, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) for biologics in daily practice psoriasis care in the first 6 months of treatment; and to identify possible differences in satisfaction with medication between patients experienced (biologics-experienced) and inexperienced (biologics-inexperienced) in the use of biologics.

Methods: TSQM baseline measurements were compared using measurements taken after 6 months, using the Wilcoxon signed-rank test for paired comparisons. Intention-to-treat with last observation carried forward (ITT with LOCF) and as-treated analyses were performed. The difference between biologics-experienced and biologics-inexperienced patients for TSQM was analysed using ITT with LOCF. At 6 months, outcomes for biologics-experienced and biologics-inexperienced patients were compared using the Mann-Whitney U-test.

Results: One hundred and six patients were eligible for analysis, and treated with etanercept (n = 34), adalimumab (n = 49) or ustekinumab (n = 23). Fifty-four per cent of patients were biologics-inexperienced. A statistically significant improvement was seen in all domains of the TSQM ('effectiveness', 'side-effects', 'convenience' and 'global satisfaction') by comparison of months 3 or 6 with baseline (all P ≤ 0·02). After 6 months, biologics-inexperienced patients scored better on the 'global satisfaction' domain than biologics-experienced patients (P < 0·01).

Conclusions: We provide a prospective, longitudinal analysis of TSQM for biologics in daily practice psoriasis care. High satisfaction rates were achieved. The 'effectiveness' and 'convenience' domains showed the most room for improvement.

PubMed Disclaimer

Publication types